Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures

Research output: Contribution to journalArticle

31 Scopus citations


Currently, there is no proven drug treatment for dry age-related macular degeneration (AMD). Several different treatment strategies are being investigated, including complement inhibition, neuroprotection, and visual cycle inhibitors, and novel clinical trial endpoints are being explored. Studies have identified genetic predispositions for dry AMD associated with complement dysfunction. Consequently, complement-based therapeutic treatment modalities are promising.

Original languageEnglish (US)
Pages (from-to)167-180
Number of pages14
JournalSeminars in Ophthalmology
Issue number3
StatePublished - May 1 2011



  • age-related macular degeneration
  • clinical trials
  • drusen
  • geographic atrophy

ASJC Scopus subject areas

  • Ophthalmology

Cite this